LON:TCF

Theracryf Final Earnings Results & Report

GBX 0.16 0.00 (-2.42%)
As of 11/20/2026 04:34 AM Eastern

Theracryf reported Final earnings on September 28, 2026. The company reported EPS of -GBX 0.16.

Earnings Announcement Details

Quarter
Final
Time
Before Market Opens

Theracryf EPS Results

Actual EPS
-GBX 0.16
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Theracryf Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Theracryf Final Earnings FAQ

Theracryf (LON:TCF) reported earnings of -GBX 0.16 per share for Final. The report was announced on Monday, September 28, 2026.

Theracryf Earnings Headlines

TheraCryf appoints new board member, issues options
Theracryf Plc (TCF.L)
A $247 tool for $7
Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full year, with no re-bills and nothing to install. The catch? He isn't trying to profit on the scanner itself. Poulos is betting that once you see it deliver the night's list, you'll want more of his work for years.tc pixel
Theracryf PLC Share Chat (TCF)
See More Theracryf Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Theracryf? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Theracryf and other key companies, straight to your email.

About Theracryf

Theracryf (LON:TCF) is a biotechnology company developing new medicines for addiction and other disorders of the brain, areas of significant unmet medical need within central nervous system (CNS) disorders. The Group’s lead programme is a novel, best-in-class orexin-1 receptor antagonist being developed as a potential treatment for addiction, including binge eating, alcohol and other substance use disorders. The programme is heavily de-risked, demonstrates superior selectivity and high receptor occupancy, and is fully funded through to clinical readiness, with regulatory submissions targeted for 2026. TheraCryf also has a dopamine transporter (DAT) modulator programme addressing fatigue of brain origin, including fatigue associated with multiple sclerosis, chemotherapy and narcolepsy. The Group also has a legacy, grant-funded, oncology programme in glioblastoma with SFX-01. TheraCryf operates a capital-light, virtual development model advancing programmes to early clinical or proof-of-concept stage before partnering with larger pharmaceutical or biotechnology companies.

View Theracryf Profile